Archive: Company News
Company News: Provecs Medical closes immuno-oncology collaboration with Medac
— Joint development of Immunalon® in urinary bladder cancer
Provecs Medical GmbH, a cancer immunotherapy company developing novel treatments to modulate the tumor microenvironment, today announced the closing of a partnership with oncology pharma company Medac Gesellschaft für klinische Spezialpräparate mbH. The partners aim to develop, manufacture and market Provec’s cancer immunotherapy lead product Immunalon® for the treatment of urinary bladder cancer.
Company News: Agena Bioscience Introduces New Lung and Colon Cancer Panels for Detection of Somatic Mutations from Liquid Biopsies and Solid Tumor Tissues
Agena Bioscience today introduced new targeted research panels for the detection of somatic mutations from lung and colon cancers. The UltraSEEK™ Lung and Colon Panels enable detection of mutations as low as 0.1% minor allele frequency (MAF) from circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). The iPLEX® HS Lung and Colon Panels enable detection of mutations as low as 1% MAF from solid tumor tissue. The new panels are now commercially available worldwide.
Company News: Cebit 2017: Computational Biologists Predict Antibiotic Resistances Using Biotech
Every year, some 25,000 people die in the European Union from antibiotic-resistant, hard to treat bacteria. Although there are diagnostic methods in place to recognize such resistances in advance, these are typically very time-consuming. Researchers from the Center for Bioinformatics at Saarland University, in cooperation with the molecular diagnostics company Curetis, are developing techniques to uncover these dangerous resistances a lot faster.
Company News: BioNTech to present interim PhaseI/II data for investigational mRNA vaccine in melanoma patients at AACR Annual Meeting 2017
– First Clinically Applicable, Systemic RNA-based Cancer Vaccine –
BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that it will present interim data from an ongoing Phase I/II clinical trial of its Lipo-MERIT vaccine in patients with malignant melanoma at the 2017 Annual Meeting of the American Association for Cancer Research (AACR), taking place April 1 – 5 in Washington, DC.